SCHEMBL4871277

SCHEMBL4871277

COC(=O)COc1ccc(C(N)C(=O)N2CCCCc3ccccc32)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.52
ALDH1A1 P00352 6/20 0.52
HTT P42858 2/20 0.52
KDM4E B2RXH2 2/20 0.52
GAA P10253 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
TP53 P04637 1/20 0.51
TSHR P16473 3/20 0.48
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
HPGD P15428 2/20 0.47
LMNA P02545 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
POLB P06746 1/20 0.46
NPSR1 Q6W5P4 2/20 0.46
THRB P10828 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4871283 0.80 MAPT (0.62) MAPTALDH1A1HTTKDM4EGAA
SCHEMBL4869942 0.77 NPSR1 (0.61) HTTKMT2AMEN1LMNASMN1; SMN2
SCHEMBL4867462 0.73 MAPT (0.66) MAPTTP53NPC1RAB9ALMNA
SCHEMBL4869702 0.70 MAPT (0.66) MAPTTP53NPC1RAB9ALMNA
SCHEMBL9530206 0.70 NOTUM (0.62) MAPTALDH1A1KDM4ETSHRKMT2A
SCHEMBL27004710 0.69 NOTUM (0.67) MAPTALDH1A1KDM4ETSHRKMT2A
SCHEMBL25517546 0.69 NOTUM (0.70) MAPTALDH1A1KDM4EGAATDP1
SCHEMBL10422952 0.69 KMT2A (0.65) MAPTALDH1A1HTTKDM4ETDP1
SCHEMBL10422953 0.69 KMT2A (0.65) MAPTALDH1A1HTTKDM4ETDP1
SCHEMBL4870794 0.69 MAPT (0.61) MAPTALDH1A1HTTKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 MAPT 3398/4885ALDH1A1 3990/4885HTT 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.